Showcasing Our Oncology Innovation: Insights from Chief Oncology Officer Dr. Jeff Legos

June 10, 2025

Pfizer recently presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - one of the world's premier global oncology conferences - where our team showcased some of the impactful research we are conducting across programs in our industry-leading Oncology portfolio.

Throughout the five-day conference, Pfizer presented more than 60 new datasets, sharing the latest research from both our marketed portfolio and our pipeline of potential next-generation cancer medicines. One highlight included unprecedented Phase 3 results for a combination regimen to help treat people living with a certain type of colon cancer, which showed that the regimen doubled median overall survival compared to standard of care.

Our Chief Oncology Officer, Jeff Legos, sat down with Investor Insights to outline some of the exciting developments Pfizer presented at the conference. Dr. Legos leads Pfizer’s Oncology Research & Development, overseeing all functions from pre-clinical to late-stage clinical development activities.

Watch this video with Dr. Legos to learn more about key advancements across Pfizer's Oncology portfolio.

This momentum brings us closer to our goal of delivering eight breakthrough cancer medicines by 2030. Visit pfizer.com/pipeline to learn more about the exciting programs we’re working on as we strive to change patients’ lives.

Forward-Looking Statements: Forward-looking statements included herein and in the accompanying video are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.